Bruno Almeida Costa

15PUBLICATIONS
46CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 02, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.

Eric Jurgens, Tala Shekarkhand, Colin Rueda

|Oct 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana

|Aug 14, 2025
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana

|Feb 26, 2025
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis.

Bruno Almeida Costa, Danai Dima, Tomer Mark

|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.

Karthik Nath, Tala Shekarkhand, David Nemirovsky

|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.

Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura

Pageof 3

Frequent Collaborators

7 joint publications

Carlyn Rose Tan

7 joint publications

Neha Korde

6 joint publications

Saad Z Usmani

6 joint publications

Gunjan Shah